Tad Tillemans
Psychiatry · Little Rock, ARNPI 1346459765
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $540,720 of the $655,949 with a category attached, or 82.4%. Otsuka America Pharmaceutical, Inc. accounts for 79.3% of it on its own, with 25 other manufacturers making up the rest. Among psychiatry clinicians in AR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,015 payments — averaging $646.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$520K
- Axsome Therapeutics, Inc.$89K
- Supernus Pharmaceuticals, Inc.$30K
- Takeda Pharmaceuticals U.S.A., Inc.$8K
- Ironshore Pharmaceuticals Inc.$5K
- AbbVie$997
- plus $3K from 20 others
What the payments were for
- Consulting fees$44,7487%
- Speaking & faculty fees$540,72082%
- Travel & lodging$52,8348%
- Food & beverage$17,4953%
- Education$1520%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REXULTI$509,050
- Auvelity$88,330
- QELBREE$28,424
- TRINTELLIX$7,704
- Jornay PM 20mg capsules (Bottle of 100)$4,364
- LYBALVI$500
- SPRAVATO$120
How this compares
$655,949 in reported general payments places this provider in the 95th percentile of 235 psychiatry providers in Arkansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 13 | $18,501 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 17 | $1,483 |
| Paliperidone ErPaliperidone | 15 | $1,406 |
| Aripiprazole | 34 | $1,278 |
| Doxepin Hcl | 33 | $1,008 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 30 | $962 |
| Clonazepam | 91 | $733 |
| Oxcarbazepine | 18 | $718 |
| Bupropion XlBupropion Hcl | 56 | $668 |
| Prazosin Hcl | 36 | $582 |
| Alprazolam | 51 | $426 |
| Olanzapine | 40 | $424 |
| Quetiapine Fumarate | 28 | $396 |
| Duloxetine Hcl | 37 | $383 |
| Escitalopram Oxalate | 56 | $363 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $997 | $18,50113 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 235 psychiatry providers in Arkansas.
Other psychiatry in Little Rock
- Leslie SmithLittle Rock$766K
- Paul WylieLittle Rock$54K
- Margaret WeissLittle Rock$29K
- Duong NguyenLittle Rock$14K
- Philip MizellLittle Rock$5K
- Richard FlaniginLittle Rock$5K
- Robert FarrellLittle Rock$4K
- Pawel KuryloLittle Rock$4K
- Gintaras AukstuolisLittle Rock$4K
- Charles LewisLittle Rock$4K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.